Περίληψη:
Inflammation has been established as an important determinant of
cardiovascular disease progression. Currently, clinical examination,
laboratory and imaging tests are invaluable for the diagnosis, prognosis
and disease monitoring. Novel inflammatory biomarkers are also used to
better restratify patients in risk groups but their potential to guide
treatment decisions and management of patients has not been extensively
evaluated. Therefore, in this review article we present the most recent
data concerning the use of inflammatory biomarkers in cardiovascular
therapeutics.
Συγγραφείς:
Tsigkou, Vicky
Siasos, Gerasimos
Oikonomou, Evangelos and
Zaromitidou, Marina
Latsios, George
Vavuranakis, Manolis and
Deftereos, Spyridon
Cleman, Michael W.
Kokkou, Eleni and
Limberi, Maria
Dimitropoulos, Stathis
Zografos, Thodoris and
Marinaki, Smaragdi
Stefanadis, Christodoulos
Tousoulis, Dimitris
